Dr Lindsay Rein comments on significant advancements in CML treatment presented at ASH 2024, particularly the approval of asciminib in both the frontline and second-line settings. This new treatment option will have a major impact on clinical care because clinicians now have a broader range of therapies, including asciminib, to consider for new patients with CML.
The key clinical question going forward is how to incorporate asciminib into treatment plans, given its promising safety and efficacy data. Another important consideration is patient tolerance of these newer therapies, with long-term data suggesting positive outcomes. Additionally, the cost of care and its impact on patient quality of life will be critical issues as novel agents are introduced alongside older, generic options.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Impact of New Approvals on CML Treatment: Insights From ASH 2024 - Medscape - Dec 27, 2024.
Comments